First‑Line and Maintenance Therapy for Metastatic Epithelial Ovarian Cancer

1. First‑Line Chemotherapy Regimen

• In patients with stage IV epithelial ovarian cancer, the European Society for Medical Oncology (ESMO) recommends six 3‑weekly cycles of paclitaxel 175 mg/m² plus carboplatin AUC 5–6 as the backbone regimen; bevacizumab 15 mg/kg is added for high‑risk disease and continued as maintenance, which improves progression‑free survival (PFS) and receives an ESMO‑MCBS score of 4. 1

• For frail patients or those with poor performance status, ESMO advises a weekly schedule of paclitaxel 60 mg/m² plus carboplatin AUC 2 to maintain efficacy while reducing toxicity. 1

2. Molecular Testing Required Before Treatment

• ESMO mandates germline and somatic BRCA1/2 mutation testing together with homologous recombination deficiency (HRD) assessment at diagnosis; results direct selection of PARP‑inhibitor maintenance and are associated with a significant survival advantage. 1

3. Risk‑Stratified Maintenance Therapy

4. Evaluation Prior to Recurrent‑Disease Management

• Before selecting therapy for recurrence, ESMO recommends assessing: prior platinum response (progression during vs. after), treatment‑free interval from last platinum (TFIp), BRCA status, prior PARP‑inhibitor exposure, residual neurotoxicity, previous bevacizumab use, performance status, and patient preferences. 3

5. Platinum‑Eligible Recurrent Disease

5.1 Surgical Consideration

• All patients with a first relapse and TFIp > 6 months should be referred to a gynecologic oncology center for evaluation of secondary cytoreductive surgery. 3
• Surgery is advised only for patients meeting a positive AGO score (complete primary resection or FIGO I–II disease, ECOG 0, ascites < 500 mL). 2
• The DESKTOP III trial demonstrated overall‑survival and PFS benefits when complete (R0) resection is achievable. 2

5.2 Systemic Therapy

• Preferred regimen for rapid disease control (and when no prior PARP‑inhibitor exposure) is carboplatin + pegylated liposomal doxorubicin (PLD) + bevacizumab (ESMO‑MCBS 3), followed by bevacizumab maintenance until symptomatic progression. 3
• This combination shows a more favorable safety profile than carboplatin‑paclitaxel, with lower rates of severe neurotoxicity and hypersensitivity reactions. 4
• Alternative platinum doublets (carboplatin + gemcitabine or carboplatin + paclitaxel) may also be used together with bevacizumab. 3

5.3 PARP‑Inhibitor Maintenance (if PARP‑naïve)

• After a response to a platinum doublet, add maintenance:
  
  • Olaparib for BRCA‑mutated tumors (ESMO‑MCBS 2) 3
  • Niraparib for any BRCA status (ESMO‑MCBS 3) 3
  • Rucaparib for any BRCA status (ESMO‑MCBS 3) 3
• Continue the chosen PARP inhibitor until disease progression or the next line of therapy; continuation beyond progression has not shown benefit. 3

5.4 Neurotoxicity Precaution

• Re‑treatment with carboplatin‑paclitaxel within 12 months should be avoided because of cumulative neurotoxicity risk. 4

6. Platinum‑Resistant (Ineligible) Disease

• Platinum‑ineligible criteria: progression during platinum, early symptomatic progression after platinum, platinum hypersensitivity/intolerance, or unacceptable quality‑of‑life impact. 3

6.1 First‑Line Platinum‑Resistant Therapy

• Weekly paclitaxel + bevacizumab is the ESMO‑preferred option (ESMO‑MCBS 4, highest benefit). 3

• Alternatives include PLD + bevacizumab or topotecan + bevacizumab; bevacizumab should be continued until symptomatic progression. 3

• If bevacizumab is contraindicated, single agents such as weekly paclitaxel, PLD, topotecan, or gemcitabine may be used. 3

6.2 Special Situations

• For patients intolerant to platinum but with TFIp > 6 months, trabectedin + PLD (ESMO‑MCBS 2; EMA‑approved) is an option. 3

6.3 Supportive Care

• Early integration of palliative care is recommended for all platinum‑resistant patients, as it improves quality of life and may extend overall survival. 3

7. Special Histologic Subtype: Low‑Grade Serous Carcinoma (LGSC)

• After first‑line platinum‑based chemotherapy, ESMO advises hormonal therapy with anti‑estrogen agents for LGSC. 2
• In recurrent LGSC that has progressed on chemotherapy and hormone therapy, trametinib (MEK inhibitor) should be considered. 3

8. Key Clinical Pitfalls (ESMO Guidance)

• Do not apply the 6‑month TFIp cutoff rigidly; patients with TFIp < 6 months may still benefit from platinum rechallenge. 2
• Monitor for platinum hypersensitivity, which occurs in ~5 % of patients and rises with repeated exposure; desensitization protocols are available. 5
• Avoid continuing bevacizumab or PARP inhibitors beyond documented disease progression outside a clinical‑trial setting. 3
• Intraperitoneal chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) are not standard first‑line options and should be limited to clinical trials. 2

Maintenance Therapy for BRCA‑Negative, HRD‑Positive Advanced Ovarian Cancer

Molecular Testing

• All newly diagnosed patients should receive both germline and somatic BRCA1/2 mutation testing and an HRD status assessment before any maintenance decision is made. (European Society for Medical Oncology (ESMO) guideline) 6
• HRD testing must be performed with a validated assay such as the Myriad myChoice CDx platform. (American Society of Clinical Oncology (ASCO) recommendation) 7

First‑Line Surgical and Chemotherapy Strategy

• Complete primary cytoreductive surgery (no visible residual disease) followed by six cycles of paclitaxel + carboplatin (paclitaxel 175 mg/m², carboplatin AUC 5‑6 q3 weeks) is the standard backbone regimen. (ESMO) 6
• For high‑risk disease (stage IV or suboptimal cytoreduction), adding bevacizumab 15 mg/kg to the chemotherapy and continuing it as maintenance improves progression‑free survival (PFS) and carries an ESMO‑MCBS score of 4. (ESMO) 6
• When complete primary cytoreduction is not feasible, neoadjuvant chemotherapy (three cycles) followed by interval cytoreductive surgery is an appropriate alternative. (ESMO) 6

Maintenance Options (BRCA‑Negative, HRD‑Positive)

Primary Recommendation – Niraparib

• Niraparib 200–300 mg once daily for up to 3 years is the preferred maintenance therapy for patients who achieve a complete or partial response to first‑line platinum‑based chemotherapy.
  
  • Evidence: PRIMA trial showed a statistically significant PFS benefit in the HRD‑positive, BRCA‑wild‑type subgroup.
  • Benefit rating: ESMO‑MCBS v1.1 = 3, ESCAT = I‑A. (ESMO) [6][7]

Alternative When Bevacizumab Was Used in First‑Line – Olaparib + Bevacizumab

• Olaparib 300 mg twice daily plus bevacizumab 15 mg/kg every 3 weeks for 2 years is recommended for patients whose first‑line regimen already included bevacizumab.
  
  • Evidence: PAOLA‑1 trial demonstrated a pronounced PFS improvement in HRD‑positive patients receiving this combination, whereas HRD‑negative patients derived no benefit (hazard ratio 1.00; 95 % CI 0.75‑1.35).
  • Benefit rating: ESMO‑MCBS v1.1 = 3, ESCAT = I‑A. (ESMO; NCCN) [6][7][8][9]

If Bevacizumab Is Contraindicated

• Niraparib monotherapy remains the recommended option for HRD‑positive, BRCA‑negative patients. (ESMO) 6
• Bevacizumab alone may be considered for HRD‑negative tumors. (ESMO) 6

Treatment Duration and Continuation Criteria

• Niraparib: up to 3 years; olaparib + bevacizumab: up to 2 years. (ESMO) 6
• Therapy should be continued until disease progression, unacceptable toxicity, or completion of the planned duration. (ASCO) 7

Toxicity Management and Safety Monitoring

• PARP‑inhibitor–related toxicities are generally manageable with dose reductions and temporary treatment interruptions. (ASCO) [10][11]
• Clinicians must monitor for rare but serious adverse events, notably therapy‑related AML/MDS, especially with prolonged PARP‑inhibitor exposure. (ASCO) 7

Maintenance in the Recurrent Setting

Platinum‑Sensitive Recurrence (≥6 months after last platinum)

• After response to platinum‑based chemotherapy, maintenance with any approved PARP inhibitor (olaparib, niraparib, or rucaparib) is strongly recommended regardless of BRCA status.
  
  • The magnitude of benefit is greatest in BRCA‑mutated disease but remains clinically significant in HRD‑positive patients. (ASCO) [10][11]

Platinum‑Resistant Recurrence

• PARP inhibitors are not FDA‑approved as monotherapy for platinum‑resistant disease; the preferred regimen is weekly paclitaxel plus bevacizumab (ESMO‑MCBS = 4). (No cited evidence for PARP use)

Evidence Quality and Guideline Authority

• The recommendations are anchored in the 2023 ESMO clinical practice guidelines and the 2020 ASCO guideline, both providing Level I evidence with Grade A strength for PARP‑inhibitor maintenance in HRD‑positive ovarian cancer. (ESMO; ASCO) [6][7]